ArticleLeukemia2017
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Dyana T Saenz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this papertrialcites it